What is HC Wainwright’s Forecast for VRDN FY2026 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Viridian Therapeutics in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($3.58) per share for the year, up from their previous forecast of ($4.28). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.64) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q4 2026 earnings at ($0.82) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.76) EPS, FY2027 earnings at ($2.45) EPS, FY2028 earnings at ($1.09) EPS, FY2029 earnings at $1.26 EPS and FY2030 earnings at $4.14 EPS.

A number of other research analysts have also recently issued reports on VRDN. Wells Fargo & Company lifted their price objective on shares of Viridian Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Thursday, November 5th. Wedbush lifted their price target on Viridian Therapeutics from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Leerink Partners boosted their price objective on Viridian Therapeutics from $50.00 to $54.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Truist Financial increased their price objective on Viridian Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Finally, Weiss Ratings upgraded Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 14th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Viridian Therapeutics Stock Performance

VRDN opened at $30.86 on Monday. The company has a current ratio of 14.46, a quick ratio of 14.46 and a debt-to-equity ratio of 0.50. The company’s fifty day moving average price is $22.27 and its two-hundred day moving average price is $21.79. Viridian Therapeutics has a 1-year low of $13.18 and a 1-year high of $34.29. The company has a market cap of $3.50 billion, a price-to-earnings ratio of -8.04 and a beta of 1.07.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative return on equity of 79.67% and a negative net margin of 1,620.79%. The company had revenue of $25.75 million for the quarter, compared to analysts’ expectations of $4.72 million.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.40% of the stock is owned by company insiders.

Institutional Trading of Viridian Therapeutics

A number of large investors have recently added to or reduced their stakes in VRDN. KBC Group NV bought a new stake in shares of Viridian Therapeutics in the 1st quarter worth approximately $34,000. Integrated Wealth Concepts LLC bought a new stake in shares of Viridian Therapeutics in the second quarter valued at $33,000. State of Wyoming bought a new stake in shares of Viridian Therapeutics in the second quarter valued at $43,000. Fulcrum Asset Management LLP purchased a new position in shares of Viridian Therapeutics during the 3rd quarter valued at $97,000. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Viridian Therapeutics during the 3rd quarter valued at $216,000.

About Viridian Therapeutics

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.